← Michelle L. O’Donoghue

Papers by Michelle L. O’Donoghue

Page 2 · newest first

51. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialJAMA Cardiology · 2020
52. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous ThromboembolismCirculation · 2020
53. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER TrialEuropean Journal of Preventive Cardiology · 2020
54. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failureNature Communications · 2020
55. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic ClassesCirculation · 2019
56. Genome-wide association study provides new insights into the genetic architecture and pathogenesis of heart failure2019
57. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskCirculation · 2019
58. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary interventionCardiovascular Research · 2019
59. Cystatin C for Risk Stratification in Patients After an Acute Coronary SyndromeJournal of the American Heart Association · 2018
60. Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular diseasePLoS ONE · 2018
61. Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trialsEuropean Heart Journal · 2018
62. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary SyndromeJAMA Cardiology · 2018
63. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndromeEuropean Journal of Preventive Cardiology · 2018
64. Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) TrialJournal of the American Heart Association · 2017
65. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary SyndromeJournal of the American Heart Association · 2017
66. Soluble interleukin-13rα1: a circulating regulator of glucoseAJP Endocrinology and Metabolism · 2017
67. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladibPLoS ONE · 2017
68. Conundrums of Platelet Function TestingCirculation Cardiovascular Interventions · 2017
69. Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) TrialJournal of the American Heart Association · 2017
70. Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated DiseasesThe American Journal of Human Genetics · 2016
71. Multimarker Risk Stratification in Patients With Acute Myocardial InfarctionJournal of the American Heart Association · 2016
72. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial InfarctionJAMA · 2016
73. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrelThrombosis and Haemostasis · 2016
74. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†European Heart Journal · 2015
75. PHILO　– Ensuring Trial Results Are Not Lost in Translation –Circulation Journal · 2015
76. Effect of Darapladib on Major Coronary Events After an Acute Coronary SyndromeJAMA · 2014
77. Biomarkers in ACS and Heart Failure: Should Men and Women Be Interpreted Differently?Clinical Chemistry · 2013
78. Lp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsCardiology and Therapy · 2013
79. AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin TherapyCirculation · 2013
80. Prognostic Utility of Secretory Phospholipase A2 in Patients with Stable Coronary Artery DiseaseClinical Chemistry · 2011
81. Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary SyndromesCirculation · 2011
82. Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery DiseaseCirculation · 2011
83. CYP2C19 Genotype and Proton Pump Inhibitors in Clopidogrel-Treated PatientsCirculation · 2011
84. Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients With Pulmonary DiseaseAmerican Journal of Clinical Pathology · 2008
85. Early Invasive vs Conservative Treatment Strategies in Women and Men With Unstable Angina and Non–ST-Segment Elevation Myocardial InfarctionJAMA · 2008
86. The future of biomarkers in the management of patients with acute coronary syndromesCurrent Opinion in Cardiology · 2008
87. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapyEuropean Heart Journal · 2008
88. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary InterventionCirculation · 2007
89. A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programmeHeart · 2007
90. Prognostic Utility of Lipoprotein-Associated Phospholipase A ₂ for Cardiovascular Outcomes in Patients With Stable Coronary Artery DiseaseArteriosclerosis Thrombosis and Vascular Biology · 2007
91. Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary SyndromesCirculation · 2006
92. Lipoprotein-Associated Phospholipase A ₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) TrialCirculation · 2006
93. Utility of Amino-Terminal Pro–Brain Natriuretic Peptide Testing for Prediction of 1-Year Mortality in Patients With Dyspnea Treated in the Emergency DepartmentArchives of Internal Medicine · 2006
94. N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failureExpert Review of Cardiovascular Therapy · 2005